Best Income Stocks to Buy for September 24th

Zacks highlighted Okeanis Eco Tankers, Nomura Holdings, and Bristol-Myers Squibb as income-oriented buy candidates following upward revisions to current-year earnings estimates. Consensus EPS estimates rose 60.9% for Okeanis over 60 days, 22.5% for Nomura, and nearly 9% for Bristol-Myers Squibb. The article is analyst-screening commentary rather than a material company-specific development, limiting likely market impact.

Analysis

This is low-information, promotional research rather than a fundamental catalyst; estimate revisions alone are insufficient without identifying the underlying drivers and the degree to which consensus has already incorporated them. The highest near-term sensitivity is likely ECO, where tanker-rate exposure can translate rapidly into earnings and distributions, but that also makes the equity a volatile proxy for spot freight rather than a durable income compounder. Treat the revision momentum as a screening signal, not confirmation of investability.

For NMR, the more relevant variables are Japan’s policy-rate path, domestic equity-market activity, and investment-banking/trading performance versus global peers. A sustained normalization of Japanese rates could improve net interest income and retail economics over 6-18 months, but a sharp JPY appreciation or risk-off episode would pressure capital-markets revenues and ADR returns. Relative exposure favors NMR over U.S. money-center banks only if Japanese market volumes and yield curves continue to normalize.

BMY’s earnings momentum does not resolve its central valuation debate: post-LOE revenue erosion versus pipeline and acquired-asset replacement. The stock can rerate on credible evidence that new-launch uptake offsets erosion earlier than modeled, but a modest consensus revision is not enough to overcome the market’s preference for higher-growth large-cap pharma. Near-term upside is likely dividend/valuation support; the 6-18 month catalyst is clinical, regulatory, and launch execution rather than another small estimate adjustment.

Contrarian view: the apparent income signal may attract yield screens precisely when underlying cash flows are most cyclical (ECO) or most structurally contested (BMY). There is no broadly actionable cross-sectional signal here until revisions are corroborated by freight rates, Japanese operating KPIs, or BMY product-level prescription and trial data.

Key Decisions for Investors

• No immediate event-driven trade from the article; require independent confirmation of the revision drivers before adding risk.
• Place ECO on a tactical watchlist for a 1-3 month long only if VLCC spot/forward rates and contracted coverage support the revised earnings base; use a 10-15% position stop because freight-rate normalization can erase distribution upside quickly. A cleaner expression is long ECO versus short FRO if ECO’s fleet utilization and dividend coverage improve faster than the peer.
• Maintain BMY as a value-income watch, not a momentum long. Add only after product-level launch data or guidance demonstrates that growth assets are closing the patent-expiry revenue gap; falsify on another material cut to medium-term revenue/FCF guidance.
• For 6-18 month Japan normalization exposure, consider a modest long NMR versus short KBE rather than outright NMR, contingent on a steeper JGB curve and sustained Japanese cash-equity/IPO activity. Exit if BOJ normalization stalls or yen strength materially offsets local equity gains for ADR holders.